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Autophagy is a highly conserved cellular process in which intracellular proteins and
organelles are sequestered and degraded after the fusion of double-membrane vesicles
known as autophagosomes with lysosomes. The process of autophagy is dependent on
autophagy-related (ATG) proteins. The role of autophagy in cancer is very complex and
still elusive. We investigated the expression of ATG proteins in benign nevi, primary and
metastatic melanoma tissues using customized tissue microarrays (TMA). Results from
immunohistochemistry show that the expression of ATG5 and ATG7 is significantly
reduced in melanoma tissues compared to benign nevi. This reduction correlated with
changes in the expression of autophagic activity markers, suggesting decreased basal
levels of autophagy in primary and metastatic melanomas. Furthermore, the analysis of
survival data of melanoma patients revealed an association between reduced ATG5 and
ATG7 levels with an unfavourable clinical outcome. Currently, the mechanisms regulating
ATG expression levels in human melanoma remains unknown. Using bioinformatic
predictions of transcription factor (TF) binding motifs in accessible chromatin of primary
melanocytes, we identified new TFs involved in the regulation of core ATGs. We then show
that nuclear respiratory factor 1 (NRF1) stimulates the production of mRNA and protein as
well as the promoter activity of ATG5 and ATG7. Moreover, NRF1 deficiency increased in
vitro migration of melanoma cells. Our results support the concept that reduced
autophagic activity contributes to melanoma development and progression, and
identifies NRF1 as a novel TF involved in the regulation of both ATG5 and ATG7 genes.
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Frangež et al. NRF1 Regulates AutophagyINTRODUCTION
Melanoma is one of the most aggressive and treatment-resistant
cancers worldwide. Despite new and promising therapeutic
strategies, such as targeted therapies using BRAF and MEK
inhibitors or novel immunotherapeutics, the prognosis of
metastatic melanoma patients remains poor and is often
associated with high tumor relapse rates. Additionally, current
prognostic factors used in the clinics are not sufficient to identify
all high-risk patients. Therefore, it is of increasing importance to
develop new early-stage prognostic and diagnostic markers
which help identify the patients at high risk of developing a
more aggressive metastatic phenotype (1).
Autophagy is a highly dynamic process that is tightly
regulated by so-called autophagy-related (ATG) proteins.
Autophagy is crucial for the maintenance of cellular
homeostasis and thus, it is no surprise that dysregulation of
the autophagic process plays a crucial role in several diseases,
including cancer. After years of research, the role of autophagy in
cancer is still elusive and seems to be controversial, since
depending on the stage and type of cancer it can have pro- or
anti-tumorigenic properties (2). One of the main roles of
autophagy as a tumor-supressing mechanism is maintaining
genome integrity. Through its recycling procedure it removes
defective proteins and organelles, such as defective
mitochondria, and therefore prevents DNA damage and
chromosomal instability, two attributes linked to cancer cell
adaptation, enabling tumor progression and resistance to
therapy (2). Two decades ago, the occurrence of a monoallelic
deletion of Beclin-1 was identified in 40 to 75% of ovarian, breast
and prostate cancers (3). A few years later, Qu and colleagues
observed that monoallelic loss of Beclin-1 in mice correlates with
high occurrence of tumors, such as hepatocellular carcinoma,
lung adenocarcinoma and B cell lymphoma (4).
On the other hand, it has been shown that cancer cells activate
autophagy in order to sustain sufficient nutrient supply due to
their high metabolic demands (5). In addition, autophagy has
been reported to support tumor cell resistance to anticancer
therapy (6). We have recently shown that several proteins
involved in the autophagic process; ATG5, Beclin-1 and BIF-1
are reduced in melanoma patients and that reduction of ATG5
and BIF-1 is associated with a less favourable patients’ outcome
(7, 8). The exact mechanism regulating autophagy and its related
proteins in melanoma, however, remains unknown.
Recently, researchers have started to uncover the broad
network of transcription factors (TF) involved in regulation of
autophagy. TF, such as transcription factor EB (TFEB), cyclic
AMP-responsive element-binding protein 1 (CREB1) or
Forkhead box O (FOXO) family of proteins, regulate the
expression of numerous genes involved in autophagy initiation,
autophagosome membrane elongation, substrate capture and
autophagosome trafficking and their fusion with lysosomes (9–
11). Interestingly, it has been demonstrated that changes in the
activity or expression of only one TF could be enough to either
suppress or induce autophagy (12).
Here we investigated the expression and transcriptional
regulation of some of the core ATG proteins. We found thatFrontiers in Oncology | www.frontiersin.org 2ATG5 and ATG7 are downregulated in primary and metastatic
melanomas as compared to benign nevi and that patients with
high levels of ATG5 and ATG7 in their tumors exhibited a better
overall survival. Moreover, consistent with the reduced levels of
ATG5 and ATG7, we found changes in the expression of
autophagic activity markers, indicating reduced autophagy in
melanomas as compared to benign nevi. Using bioinformatic
predictions, we identified NRF1 as a new potential TF involved in
the regulation of ATG5 and ATG7 and demonstrated that
knockdown of NRF1 had an impact on protein and mRNA
levels as well as promoter activity of both ATG5 and ATG7 genes.
Furthermore, we found that knockdown of NRF1 increases the
migration potential of melanoma cells. Our results emphasize the
significance of autophagy for melanoma development and
progression, and, for the first time, we provide data on the
expression of ATG7 in melanoma. Taken together, we identified
NRF1 as a novel TF involved in the regulation of ATG5 and
ATG7 in melanoma and therefore provide novel insights into the
transcriptional regulation of autophagy.MATERIALS AND METHODS
Study Design and Patients
This cohort study, aimed at investigating the role of autophagy in
the pathogenesis of cutaneous melanoma, included archived
tissue samples of consecutive melanocytic nevi, primary and
metastatic melanomas obtained between the years 2003 and 2015
from patients at the Department of Dermatology, Inselspital,
Bern, Switzerland. The tissue microarrays (TMA) containing
tissue samples from benign nevi, primary and metastatic
melanomas were constructed by the Department of Pathology,
University of Bern. In total 98 benign nevi, 72 primary
melanoma and 52 metastatic melanoma tissues were
quantified. The study was approved by the Ethics Committee
of the Canton of Bern.
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized and
rehydrated with graded ethanol dilutions, after which antigen
retrieval was carried out. Immunohistochemical staining was
performed with the Dako REAL Detection System, using the
Alkaline Phosphatase/RED kit according to the manufacturer’s
instructions (Agilent Technologies, Santa Clara, California,
USA). Staining was performed with monoclonal mouse anti-
ATG5 antibody (11C3, Nanotools, 1:100 dilution, Teningen,
DE), polyclonal rabbit anti-ATG7 antibody (Santa Cruz, 1:200
dilution, Dallas, Texas, USA), polyclonal anti-ATG16L1
(Lifespan Biosciences, 1:500 dilution, Washington, USA),
polyclonal anti-p62 (Sigma-Aldrich, 1:200 dilution, Missouri,
USA), polyclonal rabbit anti-LC3B antibody (Abgent, 1:100
dilution), and polyclonal anti-NRF1 (GeneTex, 1:50 dilution,
California, USA). The staining intensities of these proteins were
quantified as IODs using Image Pro Plus software as previously
described (13, 14) or as mean OD using QuPath software as
previously described (7, 15).August 2021 | Volume 11 | Article 721624
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SK-MEL-5 human melanoma cell lines were cultured in RPMI
1640 + GlutaMAX medium supplemented with 10% fetal bovine
serum, penicillin (100 U/mL), and streptomycin (100 mg/mL) at
5% CO2 at 37°C (all media were from Life Technologies,
Carlsbad, California, USA).
Immunoblot Analysis
Cell pellets from cultured cells were collected and lysed with the
appropriate amount of lysis buffer (50 mM Tris [pH 7.4], 150
mMNaCl, 10% Glycerol, 1% Triton X-100, 2 mM EDTA, 10 mM
NaPyrophosphate, 50 mM NaF, 200 mM Na3VO4). Lysis buffer
was prepared freshly by adding 100 mM phenylmethylsulfonyl
and a protease inhibitor cocktail (Sigma-Aldrich). The protein
concentration was measured with the BCA Protein Assay kit
(ThermoFisher Scientific, Waltham, Massachusetts, USA). 50 mg
of cell lysate were separated on 12% SDS-PAGE gels and
transferred to a polyvinylidene diuoride membrane (PVDF;
Immobilon-P membrane, Merck Millipore, Burlington,
Massachusetts, USA). After blocking in 5% milk in TBST
(0.1% Tween-20 in 0.20 M Tris, 1.50 M NaCl [pH=7.6])
membranes were incubated with primary antibodies overnight
at 4°C. Primary antibodies were purchased as follows:
monoclonal anti-ATG5 antibody (11C3, 1:1000 dilution,
Nanotools), monoclonal anti-ATG7 antibody (D12B11, 1:1000
dilution, Cell Signalling, Massachusetts, USA), monoclonal anti-
Beclin-1 antibody (D40C5, 1:1000 dilution, Cell Signalling),
polyclonal anti-NRF1 (1:500 dilution, GeneTex), polyclonal
anti-NFE2L2 (1:1000 dilution, GeneTex), polyclonal anti-p62
(1:1000 dilution, Cell Signaling), polyclonal anti-LC3B (1:1000
dilution, Novus Biologicals, Colorado, USA), and monoclonal
anti-alpha-tubulin (clone B-5-1-2, 1:5000 dilution, Sigma-
Aldrich, Missouri, USA). The membranes were washed three
times with TBST and incubated with horseradish peroxidase
(HRP)-conjugated secondary antibody (1:10000 dilution, GE
Healthcare, Illinois, USA) in blocking buffer for 1 h at room
temperature. For the detection of HRP, chemiluminescent
substrate (ECL-Plus Western Blotting Substrate, ThermoFisher
Scientific) was used. Immunoblot signals were acquired on an
Odyssey-Fc (LI-COR Biosciences, Nebraska, USA) and analysed
using Image studio lite (LI-COR Biosciences).
Quantitative Real-Time PCR
RNA was isolated with the ZR RNA MicroPrep kit (Zymo
Research, Irvine, California, USA). After reverse transcription
of isolated RNA to complementary DNA (cDNA), duplicate real-
time PCRs were performed with the iQ SYBR Green Supermix
(Bio-Rad Laboratories AG, California, USA) using the CFX
Connect real-t ime PCR detection system (Bio-Rad
Laboratories) or the Absolute Blue qPCR SYBR Green Low
ROX Mix (ThermoFisher Scientific) using the Applied
Biosystems 7500 Fast Real-Time PCR System, with 100 ng
extracted genomic DNA, and 200 nM of each primer in 10 mL
final PCR mix. The cycling variables were 3 min at 95°C followed
by 40 cycles of 10 s at 95°C and 30 s at 55°C. Human primers
were as follows: human ATG5, 5’-CAC AAG CAA CTC TGGFrontiers in Oncology | www.frontiersin.org 3ATG GGA TTG-3’ (forward) and 5’-GCA GCC ACA GGA CGA
AAC AG-3’ (reverse); human ATG7, 5’-TCG AAA GCC ATG
ATG TCG TCT T-3’ (forward) and 5’-CCA AAG CAG CAT
TGA TGA CCA-3’ (reverse); human Beclin-1, 5’-CCA GGC
GAA ACC AGG AGA GAC-3’ (forward) and 5’-GGG ATG
AAT CTG CGA GAG ACA CC-3’ (reverse); human HPRT, 5’-
TGG ACA GGA CTG AAC GTC TT-3’ (forward) and 5’-GAG
CAC ACA GAG GGC TAC AA-3’ (reverse); human NRF1, 5’-
AGC AAG CTA TTG TCC TCT GTA TCT CA-3’ (forward) and
5’-TGA GAG GCG GCA GTT CTG A-3’ (reverse); human
NFE2L2, 5’- GAC GGA AAG AGT ATG AGC TGG AA-3’
(forward) and 5’-TGC GCC AAA AGC TGC AT-3’ (reverse).
Primers were synthesized by Microsynth AG (Balgach, DE).
siRNA Transfection
SK-MEL-5 cells were transfected with Lipofectamine 2000
(Invitrogen, California, USA) according to manufacturer’s
instructions using 50 nM of gene-specific siRNAs against
human NRF1 (siNRF1) (Dharmacon M-017924-01-0005);
NFE2L2 (siNFE2L2) (Dharmacon M-003755-02-0005) or 50
nM of a negative control siRNA duplexes (siControl)
(Dharmacon, D-001206{14-05). Cells were collected 48 h after
transfection and processed for RNA extraction and protein
lysates. Nuclear factor erythroid 2-related factor 2 (NRF2), also
known as nuclear factor erythroid-derived 2-like 2, is a
transcription factor encoded by the NFE2L2 gene. To avoid
confusion with the similarly named Nuclear Respiratory Factor
1 (NRF1), NRF2 protein is called throughout the manuscript by
its gene name NFE2L2.
Dual-Luciferase Assay
SK-MEL-5 cells were co-transfected with the pGL4.15 firefly
luciferase vector containing 1 kb regions upstream of
transcription start site of ATG5, ATG7 or Beclin-1 promoter
sequences, pGL4.74 Renilla luciferase vector as an internal
control and siRNAs (SMARTpool, Dharmacon) targeting
selected transcription factors using the lipofectamine method
described above. 48 h after transfection, cells were lysed in the
luciferase lysis buffer according to the manufacturer’s
instructions (Dual-Glo Luciferase Assay System, Promega,
Dübendorf, DE) and luminescence was measured using a
GloMax reader (Promega). Luciferase activity was normalized
to that of Renilla luciferase activity.
Wound Healing Assay
SK-MEL-5 melanoma cells were transfected as described above
and were grown to 80% confluence in 24-well plates, then further
incubated overnight in RPMI 1640 medium without fetal calf
serum. A scratch was made on the cell monolayer using a plastic
P100 pipette tip. The cells were then washed with phosphate-
buffered saline (PBS) three times, and further cultured in RPMI
1640 medium. Pictures were taken immediately after the scratch
and after incubation for 24 h. The scratched area was measured
using ImageJ. The scratched area after 24 h was normalized to
the initial size at t = 0 h and presented as percentage of
wound closure.August 2021 | Volume 11 | Article 721624
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Analysis of public DNase-seq data from human primary
melanocytes generated by the Roadmap Epigenomics Mapping
Consortium (GSM774243, GSM774244, GSM1027307,
GSM1027312) {Bernstein, 2010 #402} were used. Raw data was
downloaded from the Sequence Read Archive (SRA) and
mapped to the human reference genome GRCh38.p12
downloaded from Gencode using the PALEOMIX pipeline
(16). The DNase-seq peaks were called with HOMER (17) for
each sample and the overlap between the four peak sets were
derived with the ChIPpeakAnno R package (18). Bigwig tracks
were generated with deepTools2 (19) and visualized in the
Integrative Genomics Viewer (IGV) (20). Public NRF1 ChIP-
Seq data for HeLa S3, HepG2, K562 and SK-N-SH (GSM935636,
GSM2534537, GSM2424260 and GSM1003630) from the
ENCODE project (21) were downloaded from the Gene
Expression Omnibus repository and visualized in IGV.
TEPIC
Transcription factor affinities were computed within the overlap
of all identified open-chromatin regions in the DNase-seq data
using TEPIC Version 2.2 (22, 23). Predicted TF affinities to
motifs at open chromatin regions of ATG5 and ATG7 promoters
were used to select candidate TFs. The precision of gene-based
scores computed by TEPIC with any accessible chromatin assay
have been validated using ChIP-seq data sets (22, 23).
GSE3189 Analysis
The raw gene-expression profile GSE3189 was downloaded from
the public database Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/). GSE3189 is based on the Agilent
GPL96 platform ([HG-U133A] Affymetrix Human Genome
U133A Array). GSE3189 contains 70 samples, of which 7 are
normal skin samples, 18 are benign skin lesion samples, and 45
are melanoma samples. The present study investigated only the
melanoma and benign nevi samples (24). The Pearson
correlation between the expression levels of selected TFs and
the ATGs were calculated, and only those displaying robust
association coefficients were considered for further analysis and
plotted in the heatmap (R2>0.5 or R2<0.5). The analysis was
performed on the normalized GSE3189 dataset obtained from
GEO. The tidyverse and corrr packages were used in R
version 3.6.0.
Statistical Analysis
Data from at least three independent experiments is presented as
means ± SD using Prism Software v6 (GraphPad, La Jolla,
California, USA). Significant values were represented according
to the following convention: p ≤ 0.05*; p ≤ 0.01**; p ≤ 0.001***; p
value > 0.05 was considered not significant. The follow-up data
on 102 primary and metastatic melanoma patients were divided
for analysis into two groups according to the mean expression of
ATG5, ATG7, and ATG16L1 in their tumors. The mean
expression of ATG5, ATG7 and ATG16L1 in primary and
metastatic melanomas were 101700.9 and 83535.2, 22192.5 and
8703.7, 59600.1 and 46045.8, respectively. The “high” groupFrontiers in Oncology | www.frontiersin.org 4included patients with ATG levels that were higher than the
mean value of the whole population. The “low” group included
patients with ATG levels that were lower than the mean value of
the whole population. OS was defined as the time from random
assignment to death from any cause. It was analysed with the log-
rank test and plotted as Kaplan-Meier survival curves.RESULTS
Decreased Expression of ATG5 and ATG7
in Melanoma Is Associated With Reduced
Overall Survival
In order to investigate the expression of ATG proteins and
autophagic activity markers across several stages of melanoma
biopsies, we constructed customized TMAs that contained tissue
samples from benign nevi donors as well as from primary and
metastatic melanoma patients. The expression levels of the
autophagy proteins ATG5, ATG7, ATG16L1, and two
autophagic markers, LC3B and p62, were assessed in
melanoma patients by immunohistochemistry. In agreement
with our previous results, we observed a significant decrease in
ATG5 levels from benign nevi to primary melanomas.
Interestingly, the levels of ATG5 were similarly decreased in
both primary and metastatic melanomas (Figure 1A) (13). Next,
we detected a consistent decrease in ATG7 expression from
benign nevi to primary melanomas and in contrast to ATG5, the
levels of ATG7 were further reduced in metastatic tissues
(Figure 1B). On the other hand, we did not observe any
differences in the expression of ATG16L1 between benign nevi,
primary and metastatic melanoma specimens (Figure 1C).
To investigate whether the reduction of the expression of
ATG5 and ATG7 results in reduced autophagy, we analysed in
vivo levels of LC3B and p62. The lipidated form of LC3B is
known to be bound to the inner and outer autophagosomal
membrane and it has been shown that its levels correlate with the
number of autophagosomes (25). To our knowledge, there is
currently no specific antibody available that would identify the
lipidated form of LC3B by immunohistochemistry. However,
staining of the non-lipidated form is usually weak or not
detectable (26, 27). Therefore, the LC3B staining largely
reflects the amount of lipidated LC3B. We combined the LC3B
data with an additional autophagic marker p62 and consistent
with the expression of ATG5 and ATG7, we observed markedly
lower LC3B and higher p62 levels in melanomas than in nevi,
suggesting reduced autophagic activity in melanoma cells
(Figures 2A, B). These data are in agreement with previously
published work (13, 28).
Stratification of patients according to the mean expression
levels of ATG5 and ATG7 in their tumors revealed a significantly
improved overall survival (OS) in patients with elevated ATG5
and ATG7 levels (Figures 3A, B). Given the similar levels of
ATG16L1 across all the different stages of melanoma
progression, the expression of ATG16L1 was unrelated to the
outcome of patients (Figure 3C).August 2021 | Volume 11 | Article 721624
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show that the expression of autophagic proteins involved in the
initiation and elongation phase of autophagy is reduced in
melanoma, which is accompanied with a concomitant decrease
of autophagy in these tumors. Moreover, our study, for the first
time, associates the expression of ATG7 with melanoma
development and progression. We demonstrate that the
expression of ATG7 is reduced in primary melanoma and in
contrast to ATG5, the expression of ATG7 is further reduced in
metastatic melanoma tissues.
NRF1 Is a Novel Transcription Factor
Involved in Regulation of ATG5 and ATG7
Expression in Melanoma
Recent publications demonstrated the important role of TFs in
the regulation of autophagy (9, 11, 12). We decided to search for
novel TFs regulating autophagy, and specifically ATG5 and
ATG7, in melanoma. Firstly, we set out to identify putative
TFs that could regulate ATG5 and ATG7 in healthy melanocytes.
To this end, we used existing DNase-seq data from primary
melanocytes together with the bioinformatic analysis tool TEPICFrontiers in Oncology | www.frontiersin.org 5to identify TF binding motifs located in accessible chromatin
regions proximal to the transcription start sites (TSS) of the
genes of interest (Figure 4A) (22, 23). The TF binding affinity
calculations were performed for the promoter regions found to
be reproducibly accessible across four biological replicates as
shown in Figure 4.
Interestingly, only one of the top 10 motifs with highest
affinity scores for ATG5 and ATG7 promoter regions was in
common for both genes (Tables S1, S2). This motif
corresponded to the binding site of nuclear factor 1 X-type
(NFIX), a TF best known for its role in brain development but
also implicated as tumor suppressor in various cancers (29). In
addition, the top hits for ATG5 included CREB and TFE family
motifs that can be bound by CREB1 and TFEB, TFs known to be
involved in regulation of ATG5 and several other autophagy-
regulating genes (9–11). The TF with the highest affinity score for
ATG7 promoter region was the nuclear respiratory factor-1
(NRF1). Importantly, we found ChIP-seq data for genome-
wide binding of NRF1 in HepG2, K562, SK-N-SH, and HeLa-
S3 cancer cell lines in the data from the ENCODE project
(https://www.encodeproject.org/). As predicted, we could see aA
B
C
FIGURE 1 | ATG5 and ATG7 levels are decreased in primary and metastatic melanomas compared with benign nevi. (A–C) Immunohistochemistry. Quantification of
the ATG5, ATG7, and ATG16L1 signal intensity. Intensity (integrated optical density (IOD)) values for individual patients are presented. The red lines represent the
mean of all values. Statistical differences were analysed by one-way ANOVA using a Kruskal-Wallis test and Dunn’s post hoc test (left panel). p ≤ 0.001***.
Representative images of 98, 89 and 88 benign nevi as well as 67, 69 and 67 primary and 44, 44 and 45 metastatic melanomas for ATG5, ATG7, and ATG16L1,
respectively (right panel). Scale bars 20 mm (inlets) and 50 mm.August 2021 | Volume 11 | Article 721624
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(Figure S1). Although it was not found under the top 10
candidates for ATG5 predicted by TEPIC, based on NRF1
ChIP-seq data, strong enrichment for NRF1 binding was also
seen on the TSS of ATG5 (Figure S1). Therefore, we decided to
further investigate NRF1-mediated transcriptional regulation of
ATG7 and ATG5 genes in melanoma cells. In addition to NRF1,
we also included NFE2L2 in our investigation as an internal
control TF. NFE2L2 has been shown to transcriptionally regulate
numerous genes involved in autophagy, including ATG5 and
ATG7, and is therefore next to TFEB, CREB1 and FOXO3 one of
the key regulators of autophagy (9, 10, 12, 30).
To investigate whether there is a connection between the
expression of NRF1, NFE2L2 and ATGs, we analysed existing
microarray data and investigated the gene expression profiles of
18 benign nevi and 45 primary melanoma tissue samples. We
looked into the correlation between the expression of ATG genes
and the genes of NRF1 and NFE2L2. We found that expression
levels of both TFs correlate with the studied ATGs in at least one
of the tissue types (Figure 4B).
Since our previously published and current data show
decreased expression of three of the core ATGs (ATG5, ATG7
and Beclin-1) in melanoma, we decided to study the impact of
NRF1 and NFE2L2 on the expression of these ATGs. We
performed a siRNA-mediated knockdown of NRF1 and
NFE2L2 in melanoma cells (Figure 5A). Indeed, knockdown of
NRF1 and NFE2L2 decreased the mRNA levels of ATG5, ATG7
and Beclin-1 (Figures 5B–D). Importantly, NRF1 and NFE2L2
knockdown led to a corresponding reduction in protein levels ofFrontiers in Oncology | www.frontiersin.org 6ATG5, ATG7 and Beclin-1 (Figure 5E). In addition, knockdown
of NFE2L2 resulted in a slight decrease in LC3B-II levels,
pointing to a possible reduction of autophagy (Figure 5E).
NRF1 and NFE2L2 Regulate the
Transcriptional Activity of ATG5 and ATG7
In order to confirm that the selected TFs regulate promoter
activity of the ATGs, we performed luciferase reporter assays,
where we cloned ATG5, ATG7 and Beclin-1 minimal promoter
elements (1 kb upstream from transcription start site) covering
the most important TF binding sites into a firefly luciferase
vector. We co-transfected melanoma cells with the firefly vector
containing the promoters together with the siRNAs targeting TFs
of interest. Interestingly, the luciferase assay showed that both
TFs regulate several of the studied ATG promoters
(Figures 6A–C). Specifically, we observed a decrease in
promoter activity of ATG5 and ATG7 after both NRF1 and
NFE2L2 knockdown, consistent with the results on protein and
mRNA levels. Similarly, the knockdown of NFE2L2 led to a
decrease of Beclin-1 protein, mRNA and promoter activity; while
the knockdown of NRF1 decreased Beclin-1 mRNA and protein
expression, but did not have a direct impact on its promoter
activity. This is in keeping with the investigated ENCODE ChIP-
seq data that showed a clear enrichment for NRF1 binding at the
promoters of ATG5 and ATG7, but not at Beclin-1 promoter
(Figure S1). Potentially, NRF1 could regulate Beclin-1 mRNA
and protein expression by binding to distant regulatory regions
such as enhancer regions that could not be captured in
this experiment.A
B
FIGURE 2 | Decreased LC3B and increased p62 expression in primary and metastatic melanomas compared with benign nevi. (A, B) Immunohistochemistry.
Quantification of the LC3B and p62 signal intensity. Intensity (integrated optical density (IOD)) values for individual patients are presented. The red lines represent the
mean of all values. Statistical differences were analyzed by one-way ANOVA using a Kruskal-Wallis test and Dunn’s post hoc test (left panel). p ≤ 0.05*;
p ≤ 0.01**; p ≤ 0.001***. Representative images of 88 and 75 benign nevi as well as 72 and 67 primary and 52 and 51 metastatic melanomas are shown for LC3B
and p62, respectively (right panel).August 2021 | Volume 11 | Article 721624
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staining in the same cohort of melanoma patients revealed no
difference in the expression levels of NRF1 between benign nevi,
primary and metastatic melanoma tissues (Figure 6D).
Moreover, no correlation between ATG5 and ATG7 with
NRF1 in benign nevi or melanoma tissues was observed
(Figure S2). This phenomena could be explained by altered
NRF1 activity in melanoma patients, impact of other TFs on
ATG gene expression or the involvement of post-
transcriptional regulation.
NRF1 Knockdown Increases the Migration
Potential of Melanoma Cells In Vitro
Since NRF1 and NFE2L2 have an impact on protein and mRNA
levels of several ATGs and autophagy is known to play an
important role in cancer, including influencing the epithelial-
to-mesenchymal transition (EMT), we decided to evaluate the
impact of NRF1 and NFE2L2 on the migration ability of
melanoma cells (31). With this aim, we performed a wound
healing assay on synchronized melanoma cells and compared the
migration potential between specific siRNA-mediated
knockdown of TFs and the non-targeting siRNA. Interestingly,
knockdown of NRF1 indeed increased the migration potential of
melanoma ce l l s , whi l e NFE2L2 deple t ion had no
effect (Figure 7).Frontiers in Oncology | www.frontiersin.org 7DISCUSSION
Our previous studies have suggested that autophagy plays an
important role in melanoma pathogenesis. In fact, ATG5 is
downregulated in melanoma tissues and the reduced
expression correlated with poor outcome for patients (13).
Furthermore, lowering ATG5 expression promoted
proliferation of melanoma cells by impeding oncogene-induced
senescence (13). Moreover, Beclin-1, another core ATG protein
involved in the initiation phase of autophagosome formation,
was decreased in metastatic specimens compared to primary
melanomas and benign nevi tissues (8).
In the current study, we observed a significant reduction in
ATG5 and ATG7 expression in primary and metastatic
melanomas compared to benign nevi. Furthermore, analyses of
p62 and LC3B implied lower levels of autophagy in primary and
metastatic melanomas when compared to benign nevi.
Moreover, patients exhibiting higher levels of ATG5 and ATG7
in their tumors had a better overall survival. Similarly, other
groups have recently investigated the expression of autophagic
markers and ATG proteins in melanoma using immunostaining
techniques. Mirraco et al. observed moderate to strong
cytoplasmic staining and nuclear positivity of Beclin-1 in
normal melanocytes, benign nevi, and the majority of
dysplastic nevi. Moreover, they demonstrated a moderateA B
C
FIGURE 3 | Melanoma patients with high expression of ATG5 and ATG7 in their tumors exhibited a better overall survival. (A–C) The same follow-up patients were
divided into two groups (“high” and “low”) on the basis of the mean expression of ATG5, ATG7, and ATG16L1 in their tumors. Kaplan–Meier curves for overall
survival are shown. Statistical analysis was performed using a log-rank test. The hazard ratios (HR) with their corresponding confidence intervals (95%CI) were
estimated for each group. Strata \high ATG5” [HR=0.2136;95%CI (0.0786 to 0.5806)], strata \high ATG7” [HR=0.1423;95%CI (0.0507 to 0.3995)], strata \high
ATG16L1” [HR=0.4801;95%CI (0.1773 to 1.300)].August 2021 | Volume 11 | Article 721624
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benign nevi as well as a heterogeneous LC3B expression
pattern in melanomas and metastat ic t issues (32) .
Furthermore, similarly to our results, a recent study showed
increased p62 expression in primary and metastatic melanomas
compared to benign nevi (28).
Since the expression levels of ATG5 and ATG7 are reduced in
melanoma tissues and their expression levels correlated with the
outcome of the patients, it is important to decipher the
regulatory mechanisms responsible for the observed reduction.
Currently, the details behind the regulation of the key autophagic
proteins remain mostly unknown. Only recently scientists have
started to understand the broad network of TFs involved in the
regulation of autophagy. Among the mostly studied TFs are
TFEB, a major regulator of lysosomal pathways, CREB1 and
FOXO3 (9, 10, 12). Importantly, those studies showed that
changes in expression or activity of a single TF can be
sufficient to either induce or inhibit autophagy.
Using a novel bioinformatics tool called TEPIC, we identified
putative TFs binding to promoter regions of ATG5 and ATG7.Frontiers in Oncology | www.frontiersin.org 8Our main focus was on TFs showing the highest affinity either to
ATG5 or ATG7 promoter. Elicited from our bioinformatics
analysis, the top candidate for the ATG7 promoter was NRF1.
It should be noted that NFIX was found at both promoters with
lower, but still relatively good affinity. Interestingly, ChIP-seq
data with NRF1 in 4 different cancer cell lines depicted strong
enrichment in close proximity of both ATG7 and ATG5 TSSs. In
addition to NRF1, we also investigated NFE2L2 and used it as an
internal control, since a recent study using MEFs showed that
NFE2L2 deficiency resulted in decreased expression of several
autophagy-regulating genes (30). NFE2L2 is a basic leucine
zipper TF involved in the regulation of antioxidant genes. The
role of NFE2L2 in cancer is still a matter of debate, since it has
been reported to act pro- and anti-tumorigenic (33). Our top
candidate NRF1 is one of the regulators of the cellular
antioxidant defence system and activates the expression of
some of the key genes that are required for respiration and
mitochondrial DNA transcription and replication (34). An
interesting finding was reported by Bhawe and Roy describing
that NRF1 binding motifs are present in genes implicated inA
B
FIGURE 4 | Selection of TFs with highest affinity scores for ATG5 and ATG7 promoters. (A) Prediction of binding of TFs to regulatory regions of ATG5 and ATG7
using the TEPIC tool. TF affinity scores were computed in the overlap of all DNase-seq identified open-chromatin peaks across the replicates in the proximity of the
gene-transcription start site with TEPIC. DNase-seq data from all replicates are shown. (B) Heatmap of the GSE3189 gene-expression profile showing the correlation
between NRF1 and NFE2L2 and ATG5 and ATG7. R2 values higher than 0.5 are coded in red and values lower than -0.5 are coded in blue in the Figure continuous
scale. Individual probe sets for each gene are listed.August 2021 | Volume 11 | Article 721624
Frangež et al. NRF1 Regulates AutophagyA B
D E
C
FIGURE 5 | The mRNA and protein levels of ATG5, ATG7, and Beclin-1 are influenced by siRNA knockdown of NRF1 and NFE2L2. (A) Quantitative polymerase
chain reaction (qPCR). SK-MEL-5 melanoma cells were transfected with 50 nM siRNAs (Dharmacon) against NRF1 and NFE2L2 and Non-Targeting siRNA (Control).
After 48 h NRF1 and NFE2L2 mRNA levels were determined by qPCR and normalized to HPRT mRNA levels. Statistical differences were analyzed by multiple t-test
using the Holm-Sidak correction method (n=3). (B–D) Quantitative polymerase chain reaction (qPCR). SK-MEL-5 melanoma cells were transfected as described
before and the mRNA levels of ATG5, ATG7 and Beclin-1 were determined by qPCR and normalized to HPRT mRNA levels. Statistical differences were analyzed by
multiple t-test using the Holm-Sidak correction method (n=3). p ≤ 0.05*; p ≤ 0.01**; p ≤ 0.001***. (E) Immunoblot. SK-MEL-5 melanoma cells were transfected as
described before. Expression of ATG5, ATG7, Beclin-1, LC3B, p62, NRF1, NFE2L2, and tubulin in siNRF1, siNFE2L2, and siControl cells. Lower panels:
Quantification of the immunoblots. Values were normalized to the housekeeping protein and to siControl (n=2).Frontiers in Oncology | www.frontiersin.org August 2021 | Volume 11 | Article 7216249
Frangež et al. NRF1 Regulates AutophagyFIGURE 7 | Knockdown of NRF1 increased the migration potential of melanoma cells. The wound-healing assay was made on overnight serum-starved, confluent
melanoma cells by drawing a line across the bottom of the dish. The scratch was performed on cells that were previously treated with 50 nM siRNAs (Dharmacon)
against NRF1 and NFE2L2 or Non-Targeting siRNA (siControl) for 48 h. Phase-contrast microscopy pictures were taken of the wounded area. Cell migration
quantification of pictures is represented as the empty area from t=0 h normalized to empty area from t=24 h. Statistical analysis was performed by comparing all
groups to the untreated control group using a one-way ANOVA, with Dunnett’s correction for multiple comparisons (n=3). p ≤ 0.05*. Scale 100 mm.A B C
D
FIGURE 6 | Validation of NRF1 and NFE2L2 regulation of ATG5, ATG7 and Beclin-1 promoter regions. (A–C) The Dual-Luciferase reporter plasmids (pGL4.74
[hRluc/TK] and pGL4.15[luc2P/Hygro]) were co-transfected with 50 nM siRNAs (Dharmacon) into SK-MEL-5 melanoma cells. 48 h post transfection cells were
assayed for luciferase activity. The firefly luciferase activities were normalized to renilla luciferase activity. The firefly luciferase activity of the cells transfected with
siRNAs is represented as the percentage of activity relative to that of the cells transfected with Non-Targeting siRNA (siControl). Statistical differences were analyzed
by multiple t-test using the Holm-Sidak correction method (n=3). p ≤ 0.01**; p ≤ 0.001***. (D) Immunohistochemistry. Quantification of the NRF1 signal intensity in
the nucleus. Intensity (mean optical density (meanOD)) values for individual patients are presented. The red lines represent the mean of all values. Statistical
differences were analyzed by one-way ANOVA using a Kruskal-Wallis test and Dunn’s post hoc test (left panel). Representative images of 80 benign nevi as well as
67 primary and 43 metastatic melanomas are shown (right panel). Scale bars 20 mm (inlets) and 50 mm.Frontiers in Oncology | www.frontiersin.org August 2021 | Volume 11 | Article 72162410
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major processes involved in carcinogenesis (35). In addition, a
recent study showed that knockdown of NRF1 decreased the
expression of ATG7 and overexpression of NRF1 increased
protein levels of ATG7 in nucleus pulposus (NP) cells (36).
Here we show that NRF1 indeed regulates the levels of ATG5,
ATG7 and Beclin-1 at both mRNA and protein levels. In
addition, by measuring the promoter activity of ATG5, ATG7
and Beclin-1, we validated the transcriptional regulation of NRF1
at the ATG5 and ATG7 promoters. The NRF1 ChIP-seq data
from the ENCODE project confirms the binding of NRF1 to
ATG5 and ATG7 promoter regions in 4 different cancer cells
(HepG2, K562, SK-N-SH, and HeLa-S3 cell lines). Moreover,
consistently with the results from the gene reporter assays, no
NRF1 binding was detected in the promoter region of Beclin-1.
Since NRF1 regulates protein and mRNA levels of Beclin-1 but
does not have an impact on its promoter activity, we assume that
NRF1 could regulate the Beclin-1 gene indirectly, by either
binding to distal regulatory regions or by regulating the
activity or expression of other TFs. In contrast to what we
observed in patients samples, NRF1 knockdown did not
influence autophagic activity in vitro. Perhaps knockdown of
NFR1 and the subsequent decrease of ATG5 and ATG7
expression was not strong enough to have an impact on
autophagy in vitro. Moreover, autophagy is a very complex
process and there are several factors that could influence its
levels in patients. It is unlikely that NRF1 is the sole driver of
autophagy and melanoma progression in patients. In addition,
knockdown of NRF1 could potentially result in an increase of
other TFs that induce autophagy.
As assessed by immunohistochemistry, NRF1 expression did
not show any difference between benign nevi, primary or
metastatic melanoma tissues. One of the key regulators of
NRF1 is peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PPARGC1A or PGC1a), which has been
shown to increase the NRF1 gene expression and to coactivate
the transcriptional function of NRF1 on promoters of genes such
as mitochondrial transcription factor A (mtTFA), which triggers
transcription and replication of mtDNA (37, 38). Interestingly,
elevated levels of PGC1a inversely correlates with invasive
growth in melanomas and silencing of PGC1a increases the
invasive potential of non-metastatic melanoma cells (39). Indeed,
we observed that knockdown of NRF1 leads to an increased
migration potential in melanoma cells. Moreover, PGC1a has
been shown to regulate one of the key TFs involved in regulation
of autophagy, TFEB, by occupying its promoter (40). Therefore,
it is possible that decreased NRF1 activity and consequently
expression of ATGs is the result of decreased PGC1a levels and/
or PGC1a activity in melanomas. More accessible melanoma
samples, preferably analyzed with latest functional genomics
methods would be needed to further investigate NRF1 binding.
On the other hand, silencing of NRF1 could, in addition to the
expression of ATG5 and ATG7, target several other genes, which
could positively or negatively influence the migration potential of
melanoma cells. Therefore, the impact NRF1 on the migration
could also be autophagy-independent. Indeed, knockdown ofFrontiers in Oncology | www.frontiersin.org 11NFE2L2 decreased the expression of ATGs but had no impact on
the migration potential of melanoma cells. In addition, several of
proteins regulating autophagy, including ATG5 and ATG7, have
been shown to exhibit autophagy-independent functions (41).
Taken together, the migration of melanoma cells might be
regulated by ATG5 and ATG7 independent on their role
in autophagy.
Currently, there is an immense interest in the therapeutic
modulation of autophagy, which has to be tightly regulated,
since both excess and lack of autophagy can be damaging to the
cell. Thus, it is crucial to study the mechanisms that control
autophagy in order to ensure safe therapeutic regulation in several
diseases, including cancer. In addition to our previous study where
we demonstrated decreased expression of Beclin-1 in metastatic
melanomas (8), we show here that the expression of two more
ATG proteins, ATG5 and ATG7, are reduced in primary and
metastatic melanomas compared to benign nevi. Furthermore, the
combination of LC3B and p62 expression analysis revealed that
autophagy is likely to be reduced in melanoma tissues.
Importantly, downregulation of both ATG5 and ATG7
correlates with a less favourable outcome for patients, suggesting
the potential use of ATG5 and ATG7 levels as prognostic markers
in melanoma in order to recognize the more aggressive, metastatic
phenotype. Furthermore, we identified NRF1 as a new
transcription factor involved in the regulation of ATG5 and
ATG7, improving our current understanding of the regulation
of autophagy during melanoma development and progression.DATA AVAILABILITY STATEMENT
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Frangež et al. NRF1 Regulates Autophagythe manuscript. All authors contributed to the article and
approved the submitted version.FUNDING
This work was supported by the Swiss National Science
Foundation (grant number 310030_184816) and European
Union Horizon 2020 Research and Innovation Program (Marie
Sklodowska-Curie grant No. 642295; MEL-PLEX), and Russian
Government Program “Recruitment of the Leading Scientists
into the Russian Institutions of Higher Education”, grant No.
075-15-2021-600 (H-US).Frontiers in Oncology | www.frontiersin.org 12ACKNOWLEDGMENTS
The authors acknowledge the support of the grant from the
Russian Government Program for the Recruitment of the
Leading Scientists into the Russian Institutions of Higher
Education # 075-15-2021-600.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fonc.2021.
721624/full#supplementary-materialREFERENCES
1. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R,
Hauschild A, et al. Melanoma. Lancet (2018) 392(10151):971–84.
doi: 10.1016/S0140-6736(18)31559-9
2. White E. Deconvoluting the Context-Dependent Role for Autophagy in
Cancer. Nat Rev Cancer (2012) 12(6):401–10. doi: 10.1038/nrc3262
3. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al.
Induction of Autophagy and Inhibition of Tumorigenesis by Beclin 1. Nature
(1999) 402(6762):672–6. doi: 10.1038/45257
4. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of
Tumorigenesis by Heterozygous Disruption of the Beclin 1 Autophagy Gene.
J Clin Invest (2003) 112(12):1809–20. doi: 10.1172/JCI20039
5. White E. The Role for Autophagy in Cancer. J Clin Invest (2015) 125(1):42–6.
doi: 10.1172/JCI73941
6. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. Autophagy and
Chemotherapy Resistance: A Promising Therapeutic Target for Cancer
Treatment. Cell Death Dis (2013) 4:e838. doi: 10.1038/cddis.2013.350
7. Frangez Z, Fernandez-Marrero Y, Stojkov D, Seyed Jafari SM, Hunger RE,
Djonov V, et al. BIF-1 Inhibits Both Mitochondrial and Glycolytic ATP
Production: Its Downregulation Promotes Melanoma Growth. Oncogene
(2020) 39(26):4944–55. doi: 10.1038/s41388-020-1339-8
8. Frangez Z, Seyed Jafari SM, Hunger RE, Simon HU. Loss of Concurrent
Regulation of the Expression of BIF-1, BAX, and Beclin-1 in Primary and
Metastatic Melanoma. Biochem (Mosc) (2020) 85(10):1227–34. doi: 10.1134/
S0006297920100107
9. Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, et al.
Characterization of the CLEAR Network Reveals an Integrated Control of
Cellular Clearance Pathways. Hum Mol Genet (2011) 20(19):3852–66.
doi: 10.1093/hmg/ddr306
10. Seok S, Fu T, Choi SE, Li Y, Zhu R, Kumar S, et al. Transcriptional Regulation
of Autophagy by an FXR-CREB Axis. Nature (2014) 516(7529):108–11.
doi: 10.1038/nature13949
11. Di Malta C, Cinque L, Settembre C. Transcriptional Regulation of Autophagy:
Mechanisms and Diseases. Front Cell Dev Biol (2019) 7:114. doi: 10.3389/
fcell.2019.00114
12. Fullgrabe J, Ghislat G, Cho DH, Rubinsztein DC. Transcriptional Regulation
of Mammalian Autophagy at a Glance. J Cell Sci (2016) 129(16):3059–66.
doi: 10.1242/jcs.188920
13. Liu H, He Z, von Rutte T, Yousefi S, Hunger RE, Simon HU. Down-
Regulation of Autophagy-Related Protein 5 (ATG5) Contributes to the
Pathogenesis of Early-Stage Cutaneous Melanoma. Sci Transl Med (2013) 5
(202):202ra123. doi: 10.1126/scitranslmed.3005864
14. Liu H, He Z, Bode P, Moch H, Simon HU. Downregulation of Autophagy-
Related Proteins 1, 5, and 16 in Testicular Germ Cell Tumors Parallels
Lowered LC3B and Elevated P62 Levels, Suggesting Reduced Basal
Autophagy. Front Oncol (2018) 8:366. doi: 10.3389/fonc.2018.00366
15. Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne
PD, et al. QuPath: Open Source Software for Digital Pathology Image
Analysis. Sci Rep (2017) 7(1):16878. doi: 10.1038/s41598-017-17204-516. Schubert M, Ermini L, Der Sarkissian C, Jonsson H, Ginolhac A, Schaefer R,
et al. Characterization of Ancient and Modern Genomes by SNP Detection
and Phylogenomic and Metagenomic Analysis Using PALEOMIX. Nat Protoc
(2014) 9(5):1056–82. doi: 10.1038/nprot.2014.063
17. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple
Combinations of Lineage-Determining Transcription Factors Prime Cis-
Regulatory Elements Required for Macrophage and B Cell Identities. Mol
Cell (2010) 38(4):576–89. doi: 10.1016/j.molcel.2010.05.004
18. Zhu LJ, Gazin C, Lawson ND, Pages H, Lin SM, Lapointe DS, et al.
ChIPpeakAnno: A Bioconductor Package to Annotate ChIP-Seq and ChIP-
Chip Data. BMC Bioinf (2010) 11:237. doi: 10.1186/1471-2105-11-237
19. Ramirez F, Ryan DP, Gruning B, Bhardwaj V, Kilpert F, Richter AS, et al.
Deeptools2: A Next Generation Web Server for Deep-Sequencing Data
Analysis. Nucleic Acids Res (2016) 44(W1):W160–165. doi: 10.1093/nar/
gkw257
20. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz
G, et al. Integrative Genomics Viewer. Nat Biotechnol (2011) 29(1):24–6.
doi: 10.1038/nbt.1754
21. Consortium EP. An Integrated Encyclopedia of DNA Elements in the Human
Genome. Nature (2012) 489(7414):57–74. doi: 10.1038/nature11247
22. Schmidt F, Gasparoni N, Gasparoni G, Gianmoena K, Cadenas C, Polansky
JK, et al. Combining Transcription Factor Binding Affinities With Open-
Chromatin Data for Accurate Gene Expression Prediction. Nucleic Acids Res
(2017) 45(1):54–66. doi: 10.1093/nar/gkw1061
23. Schmidt F, Kern F, Ebert P, Baumgarten N, Schulz MH. TEPIC 2-an Extended
Framework for Transcription Factor Binding Prediction and Integrative
Epigenomic Analysis. Bioinformatics (2019) 35(9):1608–9. doi: 10.1093/
bioinformatics/bty856
24. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel
Genes Associated With Malignant Melanoma But Not Benign Melanocytic
Lesions. Clin Cancer Res (2005) 11(20):7234–42. doi: 10.1158/1078-
0432.CCR-05-0683
25. Mizushima N, Yoshimori T. How to Interpret LC3 Immunoblotting.
Autophagy (2007) 3(6):542–5. doi: 10.4161/auto.4600
26. Saito T, Asai K, Sato S, Takano H, Adach A, Sasaki Y, et al. Proof of
Myocardial Autophagy by Combining Antigen Retrieval and the Avidin-
Biotin Peroxidase Complex Method. Int J Cardiol (2013) 168(5):4843–4.
doi: 10.1016/j.ijcard.2013.07.032
27. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S,
et al. Guidelines for the Use and Interpretation of Assays for Monitoring
Autophagy (4th Edition)(1). Autophagy (2021) 17(1):1–382. doi: 10.1080/
15548627.2020.1797280
28. Ellis RA, Horswell S, Ness T, Lumsdon J, Tooze SA, Kirkham N, et al. Prognostic
Impact of P62 Expression in Cutaneous Malignant Melanoma. J Invest Dermatol
(2014) 134(5):1476–8. doi: 10.1038/jid.2013.497
29. Piper M, Gronostajski R, Messina G. Nuclear Factor One X in Development
and Disease. Trends Cell Biol (2019) 29(1):20–30. doi: 10.1016/
j.tcb.2018.09.003
30. Pajares M, Jimenez-Moreno N, Garcia-Yague AJ, Escoll M, de Ceballos ML,
Van Leuven F, et al. Transcription Factor NFE2L2/NRF2 Is a Regulator ofAugust 2021 | Volume 11 | Article 721624
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